Collaboration between medac and start-up chiron to develop organ-on-chip technology

Further development and establishment of animal free testing methods for the pharmaceutical industry

12-Nov-2024 - Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further ...

Cloud-based platform for analyzing cryo-EM data secures pre-seed investment

Dutch biotech start-up aims to accelerate the development of new active ingredients

04-Mar-2024 - CryoCloud, a biotech start-up based in Utrecht in the Netherlands, recently closed a financing round of 500,000 euros. The company has thus reached an important milestone on its way to optimizing cryo-electron microscopy (cryo-EM). CryoCloud was founded in 2021 by Munich-based Robert Englmeier, ...

to-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases

05-Sep-2012 - to-BBB has been awarded funding of EUR 1.25 million by the European Commission’s 7th Framework Programme as part of a EUR 5 million consortium project for the preclinical development of novel treatments for inherited retinal degenerative diseases. The consortium additionally consists of ...

OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S

03-Feb-2012 - OctoPlus N.V. announced that a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed.

OctoPlus wins drug development and manufacturing contract from Danish pharmaceutical company

07-Jul-2011 - OctoPlus N.V. announced that a process development and manufacturing contract has been signed with a pharmaceutical company headquartered in Denmark. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.Under the contract terms, OctoPlus will perform ...

OctoPlus signs drug development contract with The Medicines Company

13-Jul-2010 - OctoPlus N.V. announced that it has signed a pharmaceutical development and manufacturing contract with a new client, US-based The Medicines Company. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues. Under the contract terms, OctoPlus will perform ...

New Consortium to Develop Drugs for Neglected Tropical Diseases

19-Aug-2009 - A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis. A total budget of nearly 3.6 million euros has been allocated over the next 4 years, to develop effective drugs for these diseases. The consortium ...

ProFibrix expands Management team and opens US subsidiary

New COO brings financing and product development experience in the US

22-Sep-2008 - ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, announced that it has added Jan Ohrstrom, MD as COO to its Executive Management team. Dr. Ohrstrom was previously part of the Senior Management team that took ZymoGenetics Inc public, and ...

Organon and Braincells to collaborate in discovery and development of CNS drugs

25-Oct-2006 - Organon, the human health care business unit of Akzo Nobel , and BrainCells Inc. (BCI) announced they will collaborate in the discovery and development of drugs for the treatment of central nervous system (CNS) disorders. BCI will use its proprietary technology in the area of neurogenesis - the ...